Exchange Traded Concepts LLC Has $170,000 Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Exchange Traded Concepts LLC lifted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 25.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,675 shares of the company’s stock after acquiring an additional 12,328 shares during the period. Exchange Traded Concepts LLC’s holdings in Allogene Therapeutics were worth $170,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in ALLO. Nisa Investment Advisors LLC increased its position in shares of Allogene Therapeutics by 429.6% during the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after acquiring an additional 8,734 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Allogene Therapeutics during the second quarter worth $29,000. Phoenix Wealth Advisors bought a new stake in shares of Allogene Therapeutics during the second quarter worth $30,000. Algert Global LLC bought a new stake in shares of Allogene Therapeutics during the second quarter worth $35,000. Finally, Rothschild Investment LLC bought a new stake in shares of Allogene Therapeutics during the second quarter worth $52,000. Institutional investors own 83.63% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ALLO. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research report on Thursday, August 15th. Oppenheimer started coverage on shares of Allogene Therapeutics in a research report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 target price for the company. Canaccord Genuity Group decreased their target price on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Citigroup raised their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $14.00 target price (down previously from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.96.

Allogene Therapeutics Price Performance

Shares of ALLO opened at $2.80 on Tuesday. The firm has a 50-day moving average of $2.65 and a 200-day moving average of $2.75. Allogene Therapeutics, Inc. has a one year low of $2.01 and a one year high of $5.78. The company has a market cap of $585.20 million, a PE ratio of -1.56 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. Analysts expect that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).